This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As pharma reps’ access to physicians continues to decline, this case study examines the effectiveness of reaching physicians through other means—the EHR. Today’s physicians struggle to balance the increasing demands of patient loads, electronic health record (EHR) systems, and time spent on administrative tasks. THE CHALLENGE.
Powered by the company’s customer relationship management system, the CGT integration hub is a platform-agnostic system that aims to improve connectivity across the CGT treatment journey, enhancing the experience for patients and healthcareproviders.
Any misstep in terms of pricing, reimbursement, or marketing could mean delays in providing therapies to the patients who need them most. Customer conversion and product uptake have largely depended upon live interactions between treating physicians and biopharma representatives (e.g., Which physicians see these patients?
From important changes to engaging physicians to finding out how new technologies will help address HCPs education needs, hear what our specialist had to say. What do you think are the most important changes to engaging physicians our industry needs to keep in mind now?
“Streaming video provides life sciences advertisers with an efficient and effective way to reach patients at any stage of treatment and can help advance their patient marketing efforts.” Biopharma marketers are following their audiences and investment in this channel continues to increase.
The drug store entered the retail clinic business in summer 2006 by acquiring Minneapolis-based MinuteClinic, an already-established chain of retail-based healthcare clinics with many locations inside CVS pharmacies.
Through this collaboration, healthcareproviders are able to access clinically relevant heart rhythm analyses and actionable reports via PaceMateLIVE to monitor at-risk patients; identify underlying arrhythmias, including atrial fibrillation (AF); and drive improvements to patient care and clinical outcomes.
Get continuous, automatic data updates to improve sales rep productivity and drive intelligent engagement with healthcareproviders. Have visibility into relationships between healthcareproviders and organisations to improve targeting, eliminate territory coverage gaps, and create account-based selling plans.
“We’re now leveraging our expertise in communicating with healthcare professionals to deliver essential information and practical tools to physicians and other healthcareproviders to help them address the challenges faced by patients with chronic illness.”
The existence of biosimilars is meant to address both the cost and access of biologics in the healthcare industry. [1] Newer biosimilars and even possibly their manufacturers will not enter the market with that same trust to use their product.
healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. In a fiercely competitive U.S.
For example, a biopharma may want to track the improvement in patient adherence to a therapy pre- and post-launch of a PSP across regions to gauge its impact. Additionally, ensuring healthcareproviders are aware of and can easily enroll patients in manufacturer cost-saving programs may be vital to patient affordability of treatment.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content